Remepy

Company Overview

Snapshot

Founded in December 2021 by Or Shoval, Michal Tsur, and Shahar Shelly, Remepy operates with 51–200 employees. The company has raised a total of $61 million across 5 funding rounds from 15 investors. In August 2026, Remepy secured a Series A financing round led by O.G. Venture Partners and M Ventures.

Business overview

Remepy is a Health Tech & Life Sciences company pioneering hybrid drugs and redefining combination therapy to deliver personalized care to patients. The company develops digital molecules, which are mobile applications containing unique digital treatment protocols. These digital molecules integrate digitized, standardized, evidence-based interventions designed to enhance brain plasticity and connectivity, balance the immune system, and drive behavioral changes. Remepy addresses disease endpoints, side effects, and comorbidities, and partners with pharmaceutical companies to bring these hybrid drugs, combining digital molecules with traditional drug components, to market.

Strategic signal

In May 2026, Remepy reported strong Phase IIa clinical trial results for Hybridopa, its first-in-class hybrid drug for Parkinson's disease. This positive clinical outcome validates the company's innovative approach to combining digital therapeutics with traditional medicine, signaling significant progress in its pipeline and potential for future therapeutic advancements in neurodegenerative diseases.

Company Intelligence Q&A

What was the most recent funding round for Remepy?

In August 2026, Remepy closed a $36 million Series A financing round. The round was led by O.G. Venture Partners and M Ventures.

What clinical trial results did Remepy announce in May 2026?

In May 2026, Remepy reported strong Phase IIa clinical trial results for Hybridopa, a hybrid drug developed for Parkinson's disease.

What strategic collaboration did Remepy announce in April 2026?

In April 2026, Remepy announced a collaboration with Merck KGaA, Darmstadt, Germany, to advance hybrid drugs across various therapeutic areas, including rare tumor programs.

What new evidence did Remepy publish in July 2026?

In July 2026, Remepy published new mechanistic findings in npj Parkinson's Disease, demonstrating Hybridopa's effect on structural connectivity in the brain of Parkinson's patients, which was associated with improved clinical outcomes.

When did Remepy raise its Seed round?

In May 2024, Remepy raised a Seed round. NFX Capital was a lead investor in this round.